Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17464344 | 0.92 | CYP3A4 (0.47) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL17464359 | 0.89 | CYP3A4 (0.45) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL19797951 | 0.89 | CYP3A4 (0.52) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL17464360 | 0.88 | CYP3A4 (0.45) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL17464374 | 0.88 | CYP3A4 (0.47) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL2845115 | 0.88 | CYP3A4 (0.45) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL10241493 | 0.85 | CYP3A4 (0.49) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL17464364 | 0.84 | CYP3A4 (0.47) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL2837312 | 0.84 | CYP3A4 (0.43) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 | |
| SCHEMBL16112629 | 0.84 | CYP3A4 (0.43) | CYP3A4CYP2C8KCNH2NR1I2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, GOT1 | CYP3A4 152/4885CYP2C8 48/4885KCNH2 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.